NCT00370513View on ClinicalTrials.gov

A Phase I Study of Pazopanib in Adult Patients With Liver Cancer

PHASE1CompletedINTERVENTIONAL

Enrollment

28

Participants

Timeline

Start Date

December 6, 2006

Primary Completion Date

April 8, 2009

Study Completion Date

April 8, 2009

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG

pazopanib

Pazopanib is a potent, multi-target receptor tyrosine kinase inhibitor of VEGFR.

Trial Locations (3)

100

GSK Investigational Site, Taipei

94115

GSK Investigational Site, San Francisco

Unknown

GSK Investigational Site, Hong Kong

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY